Rintatolimod
- Generic Name
- Rintatolimod
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 38640-92-5
- Unique Ingredient Identifier
- 94325AJ25N
- Associated Conditions
- -
- Associated Therapies
- -
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT03599453
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03403634
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT01355393
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath